- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DICOT PHARMA Aktie jetzt für 0€ handeln | |||||
| 01.07. | Dicot Pharma AB: Dicot Pharma recruits Cecilia Driving as new Chief Financial Officer | 176 | GlobeNewswire (Europe) | Uppsala, Sweden, July 1, 2026. Dicot Pharma AB announces that Cecilia Driving has been appointed as new Chief Financial Officer (CFO). She will take up the position on September 1, succeeding Björn... ► Artikel lesen | |
| 30.06. | New equity right for trading, Dicot Pharma AB | 396 | GlobeNewswire | At the request of Dicot Pharma AB, equity rights will be traded on First North Growth Market as from 01 July 2026.
Security name:
DICOT PHARMA AB TO7
Short name:
DICOT... ► Artikel lesen | |
| 25.06. | Dicot Pharma AB: Dicot Pharma receives FDA clearance to initiate the first part of the Phase 2b study with LIB-01 in the U.S. | 901 | GlobeNewswire (Europe) | Uppsala, Sweden, June 25, 2026. Dicot Pharma AB announces that the company has received clearance from the U.S. Food and Drug Administration (FDA) to initiate the first part (Part I) of the Phase 2b... ► Artikel lesen | |
| 23.06. | New last trading day for paid subscription units (BTU) of Dicot Pharma AB | 257 | GlobeNewswire | At the request of Dicot Pharma AB, the last trading day in Dicot Pharma AB's paid subscription units will be changed from 2026-06-24 to 2026-06-25.
Instrument:
Paid subscription units
Short... ► Artikel lesen | |
| 09.06. | Dicot Pharma AB: Dicot Pharma announces final outcome in the oversubscribed rights issue and carries out directed share issues | 641 | GlobeNewswire (Europe) | Uppsala, Sweden, June 9, 2026. Dicot Pharma AB announced on June 4, 2026, the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue"). Today, the company... ► Artikel lesen | |
| 04.06. | Dicot Pharma AB: Dicot Pharma announces preliminary outcome in oversubscribed rights issue | 433 | GlobeNewswire (Europe) | Uppsala, Sweden, June 4, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") today announces the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue")... ► Artikel lesen | |
| 03.06. | Decision by the Disciplinary Committee regarding Dicot Pharma AB | 238 | GlobeNewswire | Stockholm, June 3, 2026 The Disciplinary Committee of Nasdaq Stockholm has found that Dicot Pharma AB (the "Company") has not breached the rules of Nasdaq Stockholm (the "Rulebook") and has therefore... ► Artikel lesen | |
| 01.06. | Dicot Pharma AB: Dicot Pharma receives patent approval in Japan for LIB-01 | 198 | GlobeNewswire (Europe) | Uppsala, Sweden, June 1, 2026. Dicot Pharma has been granted a new patent in Japan for the active substance in LIB-01. The patent strengthens the intellectual property of the company's drug candidate... ► Artikel lesen | |
| 29.05. | Dicot Pharma AB: Dicot Pharma announces the final subscription date for units in the ongoing rights issue | 459 | GlobeNewswire (Europe) | Uppsala, Sweden, May 29, 2026. Thursday, June 4, 2026, is the final day for subscription in Dicot Pharma AB's ("Dicot Pharma" or "the Company") ongoing rights issue of units, consisting of shares and... ► Artikel lesen | |
| 27.05. | Dicot Pharma AB: Dicot Pharma receives indications of interest for approx. SEK 15.6 million from existing shareholders in the ongoing rights issue | 384 | GlobeNewswire (Europe) | Uppsala, Sweden, May 27, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") has now received indications of interest from certain major shareholders totaling approximately SEK 15.6 million in the... ► Artikel lesen | |
| 20.05. | Dicot Pharma AB: Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study | 343 | GlobeNewswire (Europe) | Uppsala, Sweden, May 20, 2026. Dicot Pharma AB announces that the company has successfully completed manufacturing of the drug candidate LIB-01 as a tablet for the planned phase 2b study, which is intended... ► Artikel lesen | |
| 19.05. | Dicot Pharma AB: Dicot Pharma publishes prospectus in connection with the forthcoming rights issue | 348 | GlobeNewswire (Europe) | Dicot Pharma AB ("Dicot Pharma" or the "Company") today, on May 19, 2026, publishes an EU Follow-on Prospectus (the "Prospectus") in connection with the rights issue of units, consisting of shares and... ► Artikel lesen | |
| 08.05. | Dicot Pharma AB: Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million | 1.015 | GlobeNewswire (Europe) | Uppsala, Sweden, May 8, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") announced on April 28, 2026 its intention to resolve on a rights issue with preferential rights... ► Artikel lesen | |
| 06.05. | Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma | 306 | GlobeNewswire (Europe) | Uppsala, Sweden, May 6, 2026. Dicot Pharma AB held its Annual General Meeting today in Uppsala where the following decisions were made.
Annual report and resultsThe meeting adopted the income statements... ► Artikel lesen | |
| 30.04. | Dicot Pharma AB: Dicot Pharma presents interim report Q1 2026 and invites to a webcast | 346 | GlobeNewswire (Europe) | Uppsala, Sweden, April 30, 2026. Dicot Pharma AB publishes its interim report for the first quarter of 2026. The report is available as an attached document and on www.dicotpharma.com. The company will... ► Artikel lesen | |
| 28.04. | Dicot Pharma AB: Dicot Pharma intends to carry out an 80% already secured rights issue of SEK 210 million | 707 | GlobeNewswire (Europe) | Uppsala, Sweden, April 28, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") intends to resolve on a rights issue of units, consisting of shares and warrants, corresponding... ► Artikel lesen | |
| 12.03. | Dicot Pharma AB: Dicot Pharma initiates tablet manufacturing ahead of phase 2b clinical study | 449 | GlobeNewswire (Europe) | Uppsala, Sweden, March 12, 2026. Dicot Pharma AB announces that the company has successfully completed the development of LIB-01 as a tablet and initiated manufacturing of tablets ahead of the upcoming... ► Artikel lesen | |
| 18.12.25 | Dicot Pharma AB: Dicot Pharma signs agreement with CRO ahead of phase 2b study with LIB-01 | 578 | GlobeNewswire (Europe) | Uppsala, Sweden, December 18, 2025. Dicot Pharma AB has signed an agreement with a global contract research organization (CRO) to prepare for the planned phase 2b clinical study of the drug candidate... ► Artikel lesen | |
| 23.10.25 | Dicot Pharma AB: Dicot Pharma Announces Positive Results from its Phase 2a Study | 606 | GlobeNewswire (Europe) | Uppsala, Sweden October 23, 2025. Today, Dicot Pharma announces positive topline results from its phase 2a study of LIB-01 for the treatment of erectile dysfunction. The outcomes demonstrated clinically... ► Artikel lesen | |
| 27.08.25 | Dicot Pharma AB: Dicot Pharma included in global stock index | 486 | GlobeNewswire (Europe) | Uppsala, Sweden, August 27, 2025. As of today, the Swedish, erectile dysfunction drug developer Dicot Pharma has been incorporated into the MSCI Global Micro Cap Index, managed by MSCI, the world's... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,950 | -0,57 % | 2. Quartal 2026: Bayer ist operativ auf Kurs und macht entscheidende Fortschritte | Der Bayer-Konzern ist auch im 2. Quartal 2026 weiter vorangekommen und verzeichnet damit ein erfolgreiches 1. Halbjahr. "Operativ sind wir auf einem guten Weg, unsere Jahresziele zu erreichen", sagte... ► Artikel lesen | |
| MERCK KGAA | 140,00 | -2,44 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Rheinmetall, Deutsche Telekom, Siemens, Airbnb & Lyft | © Foto: Julian Stratenschulte/dpa Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,390 | -0,45 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 42,010 | -0,10 % | Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 | ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL (propranolol hydrochloride)... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 80,46 | +0,26 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| DERMAPHARM | 39,750 | -1,85 % | Ihre wichtigsten Termine: Heute im Blick: Dermapharm, TAG Immobilien, Cancom, Jungheinrich, Atoss Software | © Foto: picture alliance/SvenSimon/Frank Hoermann/SVEN SIMONGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| LB PHARMACEUTICALS | 45,290 | -0,09 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into... ► Artikel lesen | |
| GSK | 22,180 | -1,68 % | GSK, Eli Lilly und Co. kaufen sich Wachstum - warum Biotech-Plattformen wieder Milliarden wert sind | ||
| KARDIGAN | 22,120 | +0,27 % | Kardigan, Inc. - 10-Q, Quarterly Report | ||
| GENERATE BIOMEDICINES | 14,280 | +0,07 % | Generate Biomedicines, Inc. - 10-Q, Quarterly Report | ||
| SCHOTT PHARMA | 22,400 | +0,45 % | Ihre wichtigsten Termine: Tui, Bechtle, Jenoptik, Douglas, Eon und Freenet mit frischen Zahlen-Updates | © Foto: Clara Margais/dpa/dpa-tmnGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| APNIMED | 24,680 | -0,76 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| OMNIAB | 3,380 | 0,00 % | OmniAb GAAP EPS of -$0.05 beats by $0.07, revenue of $13.4M beats by $8.71M | ||
| SEAPORT THERAPEUTICS | 23,450 | 0,00 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| NOVO NORDISK | 40,560 | -1,00 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen |
Das Unternehmen DICOT PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,17 % bei einem Aktienkurs von 0,013 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DICOT PHARMA AB finden Sie auf Wallstreet Online.